Elmind Capital LP Takes Position in Vaxcyte, Inc. $PCVX

Elmind Capital LP purchased a new stake in Vaxcyte, Inc. (NASDAQ:PCVX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 291,500 shares of the company’s stock, valued at approximately $13,450,000. Vaxcyte makes up approximately 4.0% of Elmind Capital LP’s investment portfolio, making the stock its 8th largest holding.

Other institutional investors and hedge funds have also bought and sold shares of the company. Smartleaf Asset Management LLC boosted its position in Vaxcyte by 156.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock worth $27,000 after buying an additional 364 shares during the period. Caitong International Asset Management Co. Ltd lifted its position in shares of Vaxcyte by 1,463.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after purchasing an additional 600 shares during the period. EverSource Wealth Advisors LLC increased its stake in shares of Vaxcyte by 33.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after acquiring an additional 184 shares in the last quarter. Allworth Financial LP lifted its position in shares of Vaxcyte by 148.9% during the 3rd quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock valued at $44,000 after acquiring an additional 731 shares during the period. Finally, Aster Capital Management DIFC Ltd acquired a new position in shares of Vaxcyte during the 3rd quarter valued at $45,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Insider Buying and Selling at Vaxcyte

In other news, CAO Elvia Cowan sold 3,000 shares of the company’s stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $60.00, for a total value of $180,000.00. Following the completion of the sale, the chief accounting officer owned 28,975 shares in the company, valued at $1,738,500. This represents a 9.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $49.52, for a total transaction of $111,420.00. Following the completion of the sale, the chief operating officer owned 158,494 shares of the company’s stock, valued at approximately $7,848,622.88. The trade was a 1.40% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 7,500 shares of company stock valued at $419,288. Company insiders own 3.30% of the company’s stock.

Vaxcyte Trading Up 2.8%

Shares of PCVX stock opened at $50.67 on Thursday. The firm has a market capitalization of $7.32 billion, a PE ratio of -7.36 and a beta of 1.24. The firm has a fifty day simple moving average of $53.74 and a two-hundred day simple moving average of $52.69. Vaxcyte, Inc. has a 12 month low of $29.08 and a 12 month high of $65.00.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($2.30) EPS for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same quarter last year, the company posted ($1.04) EPS. On average, equities analysts predict that Vaxcyte, Inc. will post -7.56 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on PCVX. BTIG Research boosted their price target on shares of Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Wednesday, April 8th. Jefferies Financial Group restated a “buy” rating on shares of Vaxcyte in a research note on Tuesday, March 10th. Finally, Wall Street Zen lowered shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 28th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $86.00.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.